SteinCares will handle all regulatory filings, registrations and commercialization of Ranibizumab in Latin America, while ...

The FDA has approved Imaavy™ (nipocalimab-aahu) for the treatment of generalized myasthenia gravis in patients aged 12 years and older who are AChR or anti-muscle-specific tyrosine kinase antibody ...

A phase II clinical trial led by the Alliance for Clinical Trials in Oncology has met its primary endpoint, demonstrating ...

Interim results from the global MATTERHORN study mark the first time an immunotherapy has demonstrated statistically ...

Following FDA approval of Imaavy, we explore promising biotech candidates in development for myasthenia gravis.

Lupin Limited partners with SteinCares to license and supply ranibizumab in Latin America, excluding Mexico and Argentina.

Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial ...

Lupin and SteinCares ink license and supply agreement for ranibizumab in Latin America: Our Bureau, Mumbai Monday, May 26, 2025, 14:10 Hrs [IST] Global Pharma major Lupin Limited ...

Lupin partners with SteinCares to commercialize Ranibizumab in Latin America, aiming to improve retinal care access.